2.7(top 20%)
impact factor
2.2K(top 10%)
papers
55.7K(top 5%)
citations
92(top 5%)
h-index
2.9(top 20%)
impact factor
2.6K
all documents
59.3K
doc citations
140(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Clinical consequences of polypharmacy in elderlyExpert Opinion on Drug Safety20141,217
2DPP-4 inhibitors: pharmacological differences and their clinical implicationsExpert Opinion on Drug Safety2014588
3Long-term side effects of glucocorticoidsExpert Opinion on Drug Safety2016479
4Safety of aerosolized amphotericin BExpert Opinion on Drug Safety2007478
5Paclitaxel: a review of adverse toxicities and novel delivery strategiesExpert Opinion on Drug Safety2007388
6An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney diseaseExpert Opinion on Drug Safety2016306
7An update on the clinical consequences of polypharmacy in older adults: a narrative reviewExpert Opinion on Drug Safety2018299
8Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysisExpert Opinion on Drug Safety2014260
9Adverse reactions to first-line antituberculosis drugsExpert Opinion on Drug Safety2006256
10A review of the efficacy and safety of oral antidiabetic drugsExpert Opinion on Drug Safety2013251
11A systematic review of the safety of probioticsExpert Opinion on Drug Safety2014250
12Statin-induced myopathy: a review and updateExpert Opinion on Drug Safety2011248
13A review of existing and emerging digital technologies to combat the global trade in fake medicinesExpert Opinion on Drug Safety2017238
14Hydroxychloroquine in systemic lupus erythematosus (SLE)Expert Opinion on Drug Safety2017236
15Statin use and cancer risk: a comprehensive reviewExpert Opinion on Drug Safety2010235
16Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety2016235
17Fluoropyrimidine-associated cardiotoxicity: revisitedExpert Opinion on Drug Safety2009220
18Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicityExpert Opinion on Drug Safety2005216
19Drug-induced phospholipidosis: issues and future directionsExpert Opinion on Drug Safety2006216
20The role of data mining in pharmacovigilanceExpert Opinion on Drug Safety2005211
21Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantineExpert Opinion on Drug Safety2014209
22Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safetyExpert Opinion on Drug Safety2006205
23Renal adverse effects of nonsteroidal anti-inflammatory drugsExpert Opinion on Drug Safety2009203
24The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanismsExpert Opinion on Drug Safety2006198
25Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactionsExpert Opinion on Drug Safety2012192
26Thiazolidinedione safetyExpert Opinion on Drug Safety2012175
27Teratogenicity of sodium valproateExpert Opinion on Drug Safety2005172
28Adverse events associated with mTOR inhibitorsExpert Opinion on Drug Safety2013172
29Safety profile of tasimelteon, a melatonin MT1and MT2receptor agonist: pooled safety analyses from six clinical studiesExpert Opinion on Drug Safety2015172
30Hydroxyurea therapy for sickle cell anemiaExpert Opinion on Drug Safety2015172
31Safety of benzodiazepines in the geriatric populationExpert Opinion on Drug Safety2004171
32Pioglitazone: side effect and safety profileExpert Opinion on Drug Safety2010170
33Safety profile of iloperidone in the treatment of schizophreniaExpert Opinion on Drug Safety2014165
34Safety and tolerability of antipsychotic polypharmacyExpert Opinion on Drug Safety2012163
35Anti-obesity drugs: a review about their effects and their safetyExpert Opinion on Drug Safety2012162
36Anthracycline cardiotoxicityExpert Opinion on Drug Safety2012161
37Idiosyncratic drug-induced liver injury: an overviewExpert Opinion on Drug Safety2007158
38EGFR TKI combination with immunotherapy in non-small cell lung cancerExpert Opinion on Drug Safety2017156
39The potential adverse effects of habitual use ofCatha edulis(khat)Expert Opinion on Drug Safety2005155
40Weight gain and antipsychotics: a drug safety reviewExpert Opinion on Drug Safety2015155
41Infection risk associated with anti-TNF-α agents: a reviewExpert Opinion on Drug Safety2015153
42Revisiting doxycycline in pregnancy and early childhood – time to rebuild its reputation?Expert Opinion on Drug Safety2016146
43Drug-induced serotonin syndrome: a reviewExpert Opinion on Drug Safety2008145
44Naloxone treatment in opioid addiction: the risks and benefitsExpert Opinion on Drug Safety2007141
45The side effects of the prostaglandin analoguesExpert Opinion on Drug Safety2007141
46How safe is the use of thiazolidinediones in clinical practice?Expert Opinion on Drug Safety2009136
47Drugs with anticholinergic properties: a current perspective on use and safetyExpert Opinion on Drug Safety2011136
48Adalimumab: a review of side effectsExpert Opinion on Drug Safety2005131
49Everolimus and sirolimus in transplantation-related but differentExpert Opinion on Drug Safety2015131
50Reactivation of hepatitis B virus with rituximabExpert Opinion on Drug Safety2005130